About this trial

This is a pragmatic, international, multi-centre, phase III open-label randomised controlled trial using an efficient, adaptive, multi-arm, multi-stage (MAMS) design. Patients will be randomised to the Control Arm (Concomitant cisplatin chemotherapy plus radiotherapy) or the Treatment Arm (Induction durvalumab plus control arm and then adjuvant durvalumab)

Patient Profile

Patients with intermediate and high-risk oropharyngeal cancer

Where’s this trial being run?

St James’s Hospital, St Luke’s Radiation Oncology Network @ St James’s Hospital, St Luke’s Radiation Oncology Network @ St Luke’s Hospital, and University Hospital Galway

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: CompARE
Number: 17-14
Full Title:

CompARE – Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer

Principal Investigator: Dr Sinead Brennan
Type: Collaborative

University of Birmingham

Recruitment Started: Global: July 2015
Ireland: July 2022
Global Recruitment Target: 785
Ireland Recruitment Target: 12